BioXcel Therapeutics (BTAI) News Today $2.24 -0.19 (-7.82%) Closing price 04:00 PM EasternExtended Trading$2.21 -0.03 (-1.34%) As of 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period BioXcel Therapeutics strengthens cash position to advance SERENITY trialMarch 11 at 6:59 PM | markets.businessinsider.comBioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaMarch 11 at 7:00 AM | globenewswire.comBioXcel Therapeutics (BTAI) Expected to Announce Quarterly Earnings on TuesdayMarch 10 at 2:10 AM | americanbankingnews.comBioXcel Therapeutics announces 33% enrollment in SERENTIY at-home Phase 3 trialMarch 7, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaMarch 7, 2025 | globenewswire.comBofA maintains BioXcel Therapeutics stock underperform ratingMarch 5, 2025 | uk.investing.comBioXcel Therapeutics Announces Closing of $14 Million Registered Direct OfferingMarch 4, 2025 | globenewswire.comBioXcel Therapeutics announces $14M registered direct offeringMarch 4, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces $14 Million Registered Direct OfferingMarch 3, 2025 | globenewswire.comBioXcel Shares Are Up Today: What's Going On?March 3, 2025 | benzinga.comBioXcel announces FDA closed inspection of TRANQUILITY II Phase 3 trial siteMarch 3, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's DementiaMarch 3, 2025 | globenewswire.comBioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RuleFebruary 28, 2025 | globenewswire.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Down 84.3% in JanuaryBioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the target of a significant decline in short interest in January. As of January 31st, there was short interest totalling 250,700 shares, a decline of 84.3% from the January 15th total of 1,600,000 shares. Currently, 9.7% of the shares of the company are sold short. Based on an average trading volume of 120,500 shares, the short-interest ratio is presently 2.1 days.February 12, 2025 | marketbeat.comBTAI stock touches 52-week low at $2.53 amid sharp annual declineFebruary 12, 2025 | msn.comBioXcel Therapeutics trading halted, news pendingFebruary 8, 2025 | markets.businessinsider.comBioXcel Therapeutics enacts 1-for-16 reverse stock splitFebruary 7, 2025 | msn.comBioXcel Therapeutics announces 1-for-16 reverse stock splitFebruary 6, 2025 | msn.comBioXcel Therapeutics Sets 1-for-16 Reverse Stock Split To Regain Nasdaq ListingFebruary 6, 2025 | markets.businessinsider.comBioXcel Therapeutics Announces Reverse Stock SplitFebruary 6, 2025 | globenewswire.comBioXcel Therapeutics provides clinical, business updateFebruary 5, 2025 | markets.businessinsider.comBioXcel Therapeutics Provides Clinical and Business UpdateFebruary 5, 2025 | finance.yahoo.comBioXcel Therapeutics advances key clinical trialsFebruary 5, 2025 | msn.comBioXcel Therapeutics stock target cut to $3 by H.C. WainwrightJanuary 30, 2025 | msn.comBioXcel Therapeutics stock hits 52-week low at $0.3January 30, 2025 | msn.comBioXcel Therapeutics price target lowered to $3 from $5 at H.C. WainwrightJanuary 30, 2025 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Bioxcel Therapeutics (BTAI)January 30, 2025 | markets.businessinsider.comBioXcel Therapeutics expands board, appoints new directorJanuary 16, 2025 | msn.comBioXcel Therapeutics files to sell 5.1M shares of common stock for holdersJanuary 10, 2025 | markets.businessinsider.comB of A Securities Downgrades BioXcel Therapeutics (BTAI)January 8, 2025 | msn.comBioXcel Therapeutics downgraded to Underperform from Buy at BofAJanuary 7, 2025 | markets.businessinsider.comBioxcel Therapeutics: Strategic Initiatives and Market Opportunities Drive Buy Rating Amid Financial ChallengesJanuary 7, 2025 | markets.businessinsider.comBioXcel Therapeutics price target lowered to $5 from $7 at CanaccordJanuary 7, 2025 | markets.businessinsider.comBioXcel Therapeutics amends credit agreement, issues new warrantsNovember 23, 2024 | investing.comBioxcel Therapeutics Restructures Credit and Strengthens LeadershipNovember 23, 2024 | markets.businessinsider.comBioXcel Prices New OfferingNovember 23, 2024 | baystreet.caBioXcel Therapeutics prices 5.6M shares at 48c in public offeringNovember 23, 2024 | markets.businessinsider.comBioXcel announces common stock and warrants offering, no amount givenNovember 22, 2024 | markets.businessinsider.comBioXcel Therapeutics Announces Pricing of $7.0 Million Public OfferingNovember 22, 2024 | globenewswire.comBioXcel Therapeutics Announces Proposed Public OfferingNovember 21, 2024 | globenewswire.comBioXcel Therapeutics Reports Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comBioXcel Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | finance.yahoo.comBioXcel Therapeutics advances Phase 3 trials of BXCL501November 13, 2024 | markets.businessinsider.comWhat's Next: BioXcel Therapeutics's Earnings PreviewNovember 13, 2024 | benzinga.comBioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024November 8, 2024 | globenewswire.comBioXcel Therapeutics to Present at ThinkEquity ConferenceOctober 29, 2024 | globenewswire.comBioXcel Therapeutics price target lowered to $5 from $7 at H.C. WainwrightOctober 22, 2024 | markets.businessinsider.comBioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress DisorderOctober 15, 2024 | globenewswire.comBioXcel Therapeutics (NASDAQ:BTAI) Stock, Short Interest ReportSeptember 28, 2024 | benzinga.com Remove Ads Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address BTAI Media Mentions By Week BTAI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BTAI News Sentiment▼0.370.71▲Average Medical News Sentiment BTAI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BTAI Articles This Week▼72▲BTAI Articles Average Week Remove Ads Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Surrozen News Forte Biosciences News Lantern Pharma News RAPT Therapeutics News Aligos Therapeutics News Xilio Therapeutics News Medicus Pharma News Prelude Therapeutics News Clene News LAVA Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BTAI) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
